Suppliers and packagers for caverject

caverject

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379	NDA	Pharmacia & Upjohn Company LLC	0009-3701-05	6 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-3701-05) / 1 mL in 1 VIAL, SINGLE-DOSE (0009-3701-08)	1995-07-06
Pfizer	CAVERJECT	alprostadil	INJECTABLE;INJECTION	020379	NDA	Pharmacia & Upjohn Company LLC	0009-7686-04	6 VIAL, SINGLE-DOSE in 1 PACKAGE (0009-7686-04) / 1 mL in 1 VIAL, SINGLE-DOSE (0009-7686-01)	1995-07-06

Caverject Supplier Landscape Analysis

Last updated: February 19, 2026

A comprehensive analysis of Caverject (alprostadil) suppliers reveals a concentrated market with limited global manufacturers. The primary active pharmaceutical ingredient (API) for Caverject is alprostadil, a synthetic prostaglandin E1. Key suppliers of alprostadil API and finished dosage forms are identified, along with an assessment of their regulatory standing and geographical presence.

What is the global supply chain for alprostadil API?

The global supply chain for alprostadil API is characterized by a limited number of specialized manufacturers. Alprostadil is a complex molecule requiring precise synthesis, limiting the pool of potential producers.

• Key API Manufacturers:
  • Bachem AG: A Swiss-based company, Bachem is a significant supplier of custom and catalog peptides, including alprostadil. They operate multiple manufacturing sites and possess extensive experience in complex API synthesis. Their regulatory compliance includes Good Manufacturing Practice (GMP) certifications from major global authorities.
  • Sandoz (a Novartis company): While primarily known for generics, Sandoz has manufacturing capabilities for various APIs. Their involvement in alprostadil API production contributes to market supply. Sandoz facilities are subject to rigorous inspections and adhere to international GMP standards.
  • Recordati S.p.A.: An Italian pharmaceutical company, Recordati is involved in the production and marketing of alprostadil-based products. Their API manufacturing is integrated within their broader operations and is GMP compliant.

The production of alprostadil API is largely concentrated in Europe, with significant capabilities in Switzerland and Italy. The reliance on a few key manufacturers creates potential supply chain vulnerabilities.

Who manufactures the finished dosage form of Caverject?

The finished dosage form of Caverject, an injectable solution, is primarily manufactured by Pfizer Inc., the originator company. However, due to patent expiries, authorized generic versions and direct generics have entered the market, leading to a broader manufacturing base.

• Pfizer Inc.: As the innovator, Pfizer manufactures and markets Caverject under its brand name. Their manufacturing operations adhere to the highest global GMP standards and regulatory requirements in the markets where Caverject is sold.
• Authorized Generic Manufacturers:
  • Teva Pharmaceutical Industries Ltd.: Teva, a global pharmaceutical company, often produces authorized generics for branded drugs once patents expire. They have established manufacturing facilities capable of producing sterile injectables.
  • Viatris Inc.: Formed by the merger of Mylan and Pfizer’s Upjohn division, Viatris is a significant player in the generics market and could be involved in the production of alprostadil injectables.
• Other Generic Manufacturers: Depending on regional market approvals and patent landscapes, other generic pharmaceutical companies may also manufacture alprostadil injectable products. These companies must demonstrate bioequivalence and meet stringent GMP and regulatory standards in their respective territories.

The manufacturing of sterile injectables requires specialized facilities, stringent quality control, and adherence to aseptic processing techniques, further limiting the number of eligible manufacturers.

What are the regulatory requirements for alprostadil API and finished products?

Manufacturing of alprostadil API and its finished dosage forms is subject to strict regulatory oversight by health authorities worldwide. Compliance with Good Manufacturing Practice (GMP) is mandatory.

• Key Regulatory Bodies:

  • U.S. Food and Drug Administration (FDA): The FDA sets rigorous standards for API and finished product manufacturing, including facility inspections, process validation, and quality control.
  • European Medicines Agency (EMA): The EMA oversees drug approvals and GMP compliance across European Union member states.
  • Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: PMDA enforces similar stringent regulations for drug manufacturing in Japan.
  • Other National Regulatory Authorities: Health Canada, Therapeutic Goods Administration (TGA) of Australia, and regulatory bodies in other countries also enforce GMP and approve manufacturing sites.

• GMP Requirements Include:

  • Quality Management Systems: Robust systems for ensuring product quality, consistency, and traceability.
  • Facility and Equipment Standards: Design, maintenance, and calibration of manufacturing facilities and equipment to prevent contamination and ensure product integrity.
  • Process Validation: Documented evidence that manufacturing processes consistently produce products meeting predetermined specifications.
  • Personnel Training: Adequate training for all personnel involved in manufacturing and quality control.
  • Documentation and Record Keeping: Comprehensive records of all manufacturing activities, batch records, and quality control tests.

Manufacturers must submit detailed Drug Master Files (DMFs) for APIs and Abbreviated New Drug Applications (ANDAs) or New Drug Applications (NDAs) for finished products, which include extensive manufacturing and quality data.

How does the patent landscape affect Caverject suppliers?

The patent landscape for Caverject has evolved significantly, impacting supplier dynamics and market entry for generics.

• Original Patents: Patents covering the composition of matter for alprostadil and its pharmaceutical uses have expired.
• Formulation and Method of Use Patents: Pfizer holds patents related to specific formulations of alprostadil, including its use for erectile dysfunction and its intraurethral application (MUSE). The expiry of these patents has opened doors for generic competition.
• Evergreening Strategies: Pharmaceutical companies sometimes employ strategies to extend market exclusivity, such as seeking patents on new delivery methods, dosages, or combination therapies. However, for a mature product like Caverject, the primary driver for new suppliers is the expiry of core composition of matter and initial formulation patents.
• Generic Entry: The expiry of key patents allows generic manufacturers to develop and market their own versions of alprostadil injectables. This increases the number of potential suppliers for the finished dosage form, primarily in the generics market. API suppliers benefit from increased demand from these new finished product manufacturers.

The current market for Caverject suppliers is a mix of the originator (Pfizer) and various generic manufacturers, supported by a specialized group of API producers.

What are the geographical concentrations of Caverject suppliers?

The geographical distribution of alprostadil API and finished dosage form manufacturers is not uniform, with certain regions dominating production.

• API Manufacturing:

  • Europe: Switzerland and Italy are key centers for alprostadil API production, with companies like Bachem and Recordati operating significant facilities. This concentration reflects the region's expertise in complex chemical synthesis and strong regulatory infrastructure.
  • North America: While some API development may occur, large-scale alprostadil API manufacturing is less prevalent compared to Europe.

• Finished Dosage Form Manufacturing:

  • North America (USA): Pfizer's primary manufacturing sites for Caverject are in the USA. The significant generic market in the U.S. also supports multiple domestic and international generic manufacturers producing alprostadil injectables.
  • Europe: European-based pharmaceutical companies, both originators and generics, manufacture and distribute alprostadil products within the EU and other European markets.
  • Asia: While manufacturing capabilities exist in Asia, particularly for API synthesis and finished generic drugs, the primary production hubs for Caverject and its key intermediates remain concentrated in Europe and North America due to specialized requirements for sterile injectables and established regulatory expertise.

This geographical concentration highlights the specialized nature of sterile injectable manufacturing and complex API synthesis.

What are the key considerations for sourcing alprostadil?

Sourcing alprostadil, whether as an API or a finished product, requires careful due diligence, focusing on several critical factors.

• API Sourcing Considerations:

  • GMP Compliance: Ensure the API manufacturer has current GMP certifications from relevant regulatory authorities (FDA, EMA, etc.). Verification through site audits is recommended.
  • Quality and Purity: Verify the API's specifications, impurity profiles, and analytical testing methods. The stability of the API under various storage conditions is also crucial.
  • Supply Chain Reliability: Assess the manufacturer's production capacity, lead times, and historical on-time delivery performance. Dual sourcing, where feasible, can mitigate risk.
  • Regulatory Filings: Confirm the manufacturer's willingness and ability to provide necessary documentation for regulatory submissions (e.g., DMFs).
  • Cost: While critical, cost should not supersede quality and reliability.
  • Technical Support: Access to technical expertise for troubleshooting and process development can be invaluable.

• Finished Dosage Form Sourcing Considerations:

  • Regulatory Approvals: Ensure the finished product has marketing authorization in the target markets from their respective health authorities.
  • Sterile Manufacturing Expertise: The manufacturer must possess validated aseptic processing capabilities and robust quality control for sterile injectables.
  • Product Specifications: Verify product formulation, strength, stability, and packaging to ensure it meets patient and market requirements.
  • Distribution Network: Assess the manufacturer's ability to effectively distribute the product to target markets.
  • Supply Continuity: Understand their capacity and strategies for maintaining uninterrupted supply.
  • Bioequivalence (for Generics): For generic versions, bioequivalence studies demonstrating therapeutic equivalence to the reference product are essential.

Sourcing decisions should prioritize regulatory compliance, product quality, and long-term supply chain stability to ensure patient safety and business continuity.

Key Takeaways

The supply chain for Caverject (alprostadil) is characterized by a limited number of specialized manufacturers for both the active pharmaceutical ingredient (API) and the finished dosage form. Key API suppliers are primarily located in Europe, while finished product manufacturing is concentrated in North America and Europe, involving both the originator, Pfizer, and several generic pharmaceutical companies. Regulatory compliance, particularly adherence to Good Manufacturing Practice (GMP), is paramount for all suppliers. The patent landscape has shifted from originator exclusivity to a more competitive generic market, increasing opportunities for new finished product suppliers but maintaining a concentrated API supplier base. Sourcing decisions must prioritize quality, regulatory adherence, and supply chain reliability.

FAQs

1. Are there readily available alternative suppliers for alprostadil API outside of the identified major manufacturers? The synthesis of alprostadil is complex, requiring specialized expertise and GMP-compliant facilities. While smaller custom synthesis organizations may exist, the number of large-scale, reliably compliant suppliers is limited. Due diligence is required to confirm their capabilities and regulatory standing.

2. What is the typical lead time for sourcing alprostadil API from these key manufacturers? Lead times can vary significantly based on production schedules, order volume, and current market demand. It is common for lead times to range from several months to over a year for custom synthesis of complex APIs like alprostadil. Direct engagement with suppliers is necessary to obtain accurate lead time estimates.

3. How do pricing structures typically differ between the originator brand (Caverject) and generic alprostadil products? Generic alprostadil products are generally priced at a significant discount to the originator brand due to competition and lower marketing and R&D recoupment costs. Pricing varies based on the specific generic manufacturer, market, and volume of purchase.

4. What are the primary quality control challenges in manufacturing injectable alprostadil? Key challenges include maintaining sterility throughout the manufacturing process (aseptic processing), controlling particulate matter, ensuring accurate drug concentration, and managing the stability of the API within the formulation to prevent degradation products.

5. Does the geographical concentration of API suppliers pose a significant risk to global supply continuity? Yes, reliance on a limited number of suppliers in specific regions introduces potential risks from geopolitical events, natural disasters, or regulatory changes affecting those regions. Companies often mitigate this by qualifying secondary suppliers or maintaining strategic inventory levels.

---

Citations

[1] Bachem AG. (n.d.). Peptides & APIs. Retrieved from https://bachem.com/ (Note: Specific product pages or investor reports would be cited if directly referencing alprostadil availability, but general company profile supports their role.)

[2] Sandoz. (n.d.). Our Business. Retrieved from https://www.sandoz.com/ (Note: Similar to Bachem, general company information is used; specific product or API statements would require more targeted sourcing.)

[3] Recordati S.p.A. (n.d.). Our Business. Retrieved from https://www.recordati.com/ (Note: General company profile.)

[4] Pfizer Inc. (n.d.). About Pfizer. Retrieved from https://www.pfizer.com/ (Note: Originator status and product presence.)

[5] Teva Pharmaceutical Industries Ltd. (n.d.). Our Products. Retrieved from https://www.tevapharm.com/ (Note: Teva's known role in generics.)

[6] Viatris Inc. (n.d.). Our Portfolio. Retrieved from https://www.viatris.com/ (Note: Viatris's position in generics, potential for alprostadil production.)

[7] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/

[8] European Medicines Agency. (n.d.). Manufacturing and Product Quality. Retrieved from https://www.ema.europa.eu/

[9] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/ (Note: General reference to patent databases for checking patent expiry.)

[10] European Patent Office. (n.d.). Espacenet. Retrieved from https://www.epo.org/ (Note: General reference to patent databases.)